B+
Bull case
20%
Probability
Target price
$0.50
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
BIOX
Bioceres Crop SolutionsANasdaq / Materials
Last Price
Quote time unavailable
AI scenario view
RankAlpha Sentiment CodexMost likely
B
Base case
45%
Probability
Target price
$0.27
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
B-
Bear case
35%
Probability
Target price
$0.08
Analysis reference price unavailable
Analysis 2026-10-23 · RankAlpha Sentiment Codex
The current persistence contract does not provide an exact AI reference price. RankAlpha therefore does not calculate scenario return from the live quote. How scenarios are presented
AI sentiment snapshot
Latest data as of 2026-10-23
Recent news sentiment (30D)
+19.9
Positive
Company
-
Unavailable
Macro
+19.9
Positive
Pulse
-
Unavailable
Weekly research (10D)
-24.0
Negative
Sentiment proxy
+61.5
Score
AI commentary
Company-confirmed Q4 stabilization is outweighed by weak full-year results, leverage, litigation and listing risk. The deterministic prior is mildly positive but has low evidence quality (0.34), high uncertainty (0.713) and limited thesis change (0.14), supporting monitoring rather than a bullish upgrade. A dependable post-release price reaction, consensus-surprise comparison and post-print analyst revisions were not established. Social, options, short-interest and employee measures are unavailable; zero entries above denote missing data, not neutral readings.
RankAlpha Sentiment Codex - 2026-10-23
Open full AI memoEvidence flagged
No evidence quality warning is currently attached to this memo.
Impact
standard
Confidence
-
AI events
2026-12-31catalystTest whether the fourth-quarter operating improvement persistsHigh impact
Fiscal Q4 2026 continuing-operations revenue was $55.9 million, broadly flat year over year, and adjusted EBITDA improved to $0.6 million from negative $9.6 million as SG&A fell 19%. Crop Nutrition grew 36%, but Seeds fell 43% and reported gross margin was 22.8% after a $4 million inventory-obsolescence adjustment. Subsequent results must show whether the improvement persists; the date is an assessment horizon, not a confirmed reporting date. [#PR-2026-09-14] Company earnings release filed with the SEC
2027-03-15eventNasdaq minimum-bid-price compliance deadlineHigh impact
Nasdaq granted BIOX until March 15, 2027 to regain compliance with its $1 minimum closing bid-price requirement. A reverse split is an option, not an announced decision. Failure to demonstrate compliance could result in a delisting notice, subject to appeal. [#SEC-6K-2026-09-15] SEC Form 6-K
2027-06-30catalystPortfolio reset and cash-generation testHigh impact
Management says the Seeds reconfiguration is substantially complete and plans to rationalize products, align R&D spending with financial objectives, and improve cash generation. Fiscal 2026 revenue nevertheless fell 18%, while net financial debt was $213.6 million at June 30, 2026. Fiscal year-end is an assessment horizon, not a promised milestone. [#PR-2026-09-14] Company earnings release filed with the SEC
Recommendation
N/A
No formal recommendation provided.
As of 2026-10-23 • Updated nightlySource: Internal modelMethodology